Biologics Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size and Key Geographical Regions

1.1. Biopharmaceutical Contract Manufacturing Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

5.1. Chapter Overview
5.2. Overview of Biopharmaceuticals
5.3. Expression Systems for Biopharmaceuticals
5.3.1. Insect Expression Systems
5.3.2. Mammalian Expression Systems
5.3.3. Microbial Expression Systems
5.3.3.1. Bacterial Expression Systems
5.3.3.2. Fungal Expression Systems
5.3.3.3. Yeast Expression Systems
5.3.4. Plant Expression Systems
5.3.5. Mammalian versus Microbial Expression Systems
5.4. Manufacturing Process of Biopharmaceuticals
5.4.1. Upstream Processing
5.4.2. Fermentation
5.4.3. Downstream Processing
5.5. Overview of Contract Manufacturing
5.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
5.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
5.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations
5.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
5.7. Key Considerations While Selecting a Contract Manufacturing Partner
5.8. Future Perspectives

6.1. Chapter Overview
6.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of Service Offered
6.2.5. Analysis by Type of Biologic Manufactured
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Type of Expression System Used
6.2.8. Analysis by Type of Bioreactor Used
6.2.9. Analysis by Mode of Operation of Bioreactor

7.1. Chapter Overview
7.2. Key Assumptions and Parameter
7.3. Overview of Biopharmaceutical Contract Manufacturing Facilities
7.3.1. Analysis by Type of Service Offered
7.3.2. Analysis by Scale of Operation
7.4. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
7.5. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
7.6. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
7.7. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World

8.1. Chapter Overview
8.2. Biopharmaceutical Contract Manufacturing in the US: Regulatory Scenario
8.3. Leading Biopharmaceutical CMOs in North America
8.3.1. AGC Biologics
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.2.1. Process Development
8.3.1.2.2. cGMP Manufacturing
8.3.1.2.3. Quality and Regulatory Services
8.3.1.2.4. Process Validation
8.3.1.3. Financial Information
8.3.1.4. Manufacturing Facilities
8.3.1.5. Recent Developments and Future Outlook
8.3.2. Catalent
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.2.2.1. Cell Line Development
8.3.2.2.2. Biomanufacturing
8.3.2.2.3. ADCs and Bioconjugates Manufacturing
8.3.2.2.4. Biosimilars Development and Manufacturing
8.3.2.2.5. Fill / Finish Solutions and Delivery Services
8.3.2.2.6. Analytical Services
8.3.2.3. Clinical Supply Services
8.3.2.4. Financial Information
8.3.2.5. Manufacturing Facilities
8.3.2.6. Recent Developments and Future Outlook
8.3.3. FUJIFILM Diosynth Biotechnologies
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.2.1. Strain Development
8.3.3.2.2. Process Development
8.3.3.2.3. cGMP Manufacturing
8.3.3.2.4. Analytical Solutions
8.3.3.3. Financial Information
8.3.3.4. Manufacturing Facilities
8.3.3.5. Recent Developments and Future Outlook
8.3.4. KBI Biopharma
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio
8.3.4.2.1. Process Development
8.3.4.2.2. Analytical Development
8.3.4.2.3. GMP Manufacturing
8.3.4.2.4. Clinical Cell Therapy Support
8.3.4.3. Manufacturing Facilities
8.3.4.4. Recent Developments and Future Outlook
8.3.5. Charles River Laboratories
8.3.5.1. Company Overview
8.3.5.2. Service Portfolio
8.3.5.2.1. Cell Sourcing
8.3.5.2.2. Cell and Gene Therapy Solutions
8.3.5.2.3. Biologics Testing Solutions
8.3.5.2.4. Avian Vaccine Services
8.3.5.2.5. QC Microbial Solutions
8.3.5.2.6. Scientific and Regulatory Advisory Services
8.3.5.3. Financial Information
8.3.5.4. Manufacturing Facilities
8.3.5.5. Recent Developments and Future Outlook
8.4. Other Leading Biopharmaceutical CMOs in North America
8.4.1. Cytiva
8.4.1.1. Company Overview
8.4.2. Patheon
8.4.2.1. Company Overview
8.4.3. Piramal Pharma Solutions
8.4.3.1. Company Overview

9.1. Chapter Overview
9.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
9.2.1. EMA’s cGMP Regulations
9.3. Leading Biopharmaceutical CMOs in Europe
9.3.1. Boehringer Ingelheim (BioXcellence)
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.1.2.1. Process Development
9.3.1.2.1.1. Expression Systems
9.3.1.2.1.2. Upstream Technology
9.3.1.2.1.3. Downstream Technology
9.3.1.2.1.4. Other Process Development Services
9.3.1.2.2. Quality Assurance
9.3.1.2.3. Fill / Finish Services
9.3.1.3. Financial Information
9.3.1.4. Manufacturing Facilities
9.3.1.5. Recent Developments and Future Outlook
9.3.2. Lonza
9.3.2.1. Company Overview
9.3.2.2. Service Portfolio
9.3.2.3. Manufacturing Services
9.3.2.4. Financial Information
9.3.2.5. Manufacturing Facilities
9.3.2.6. Recent Developments and Future Outlook
9.3.3. Sandoz
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.3.3. Financial Information
9.3.3.4. Manufacturing Facilities
9.3.3.5. Recent Developments and Future Outlook
9.3.4. Vetter Pharma
9.3.4.1. Company Overview
9.3.4.2. Service Portfolio
9.3.4.3. Manufacturing Facilities
9.3.4.4. Recent Developments and Future Outlook
9.3.5. Miltenyi Biotec
9.3.5.1. Company Overview
9.3.5.2. Service Portfolio
9.3.5.3. Manufacturing Facilities
9.3.5.4. Recent Developments and Future Outlook
9.4. Other Leading Biopharmaceutical CMOs in Europe
9.4.1. Novasep
9.4.1.1. Company Overview
9.4.2. Olon
9.4.2.1. Company Overview
9.4.3. Rentschler Biopharma
9.4.3.1. Company Overview

10.1. Chapter Overview
10.2. Biopharmaceutical Contract Manufacturing in China
10.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
10.3. Leading Biopharmaceutical CMOs in China
10.3.1. WuXi Biologics
10.3.1.1. Company Overview
10.3.1.2. Service Portfolio
10.3.1.2.1. Discovery Services
10.3.1.2.2. Development Services
10.3.1.2.3. Testing Services
10.3.1.2.4. Clinical Manufacturing Services
10.3.1.3. Financial Information
10.3.1.4. Manufacturing Facilities
10.3.1.5. Recent Developments and Future Outlook
10.4. Biopharmaceutical Contract Manufacturing in India
10.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
10.5. Leading Biopharmaceutical CMOs in India
10.5.1. Kemwell Biopharma
10.5.1.1. Company Overview
10.5.1.2. Service Portfolio
10.5.1.2.1. Development Services for Biopharmaceuticals
10.5.1.2.2. Manufacturing Services for Biopharmaceuticals
10.5.1.3. Manufacturing Facilities
10.5.1.4. Recent Developments and Future Outlook
10.6. Biopharmaceutical Contract Manufacturing in Japan
10.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario
10.7. Leading Biopharmaceutical CMOs in Japan
10.7.1. Minaris Regenerative Medicine
10.7.1.1. Company Overview
10.7.1.2. Service Portfolio
10.7.1.2.1. Manufacturing Development Services
10.7.1.2.2. GMP Manufacturing
10.7.1.3. Manufacturing Facilities
10.7.1.4. Recent Developments and Future Outlook
10.8. Biopharmaceutical Contract Manufacturing in South Korea
10.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario
10.9. Leading Biopharmaceutical CMOs in South Korea
10.9.1. Samsung Biologics
10.9.1.1. Company Overview
10.9.1.2. Service Portfolio
10.9.1.2.1. Process Development
10.9.1.2.2. Analytical Services
10.9.1.2.3. cGMP Manufacturing Services
10.9.1.2.4. Aseptic Fill / Finish Services
10.9.1.2.5. Quality Services
10.9.1.3. Financial Information
10.9.1.4. Manufacturing Facilities
10.9.1.5. Recent Developments and Future Outlook
10.10. Biopharmaceutical Contract Manufacturing in Australia
10.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario
10.11. Leading Biopharmaceutical CMOs in Australia
10.11.1. Cell Therapies
10.11.1.1. Company Overview
10.11.1.2. Service Portfolio
10.11.1.3. Manufacturing Facilities
10.11.1.4. Recent Developments and Future Outlook
10.12. Other Leading Biopharmaceutical CMOs in Asia-Pacific and Rest of the World
10.12.1. AcuraBio (Formerly Known as Luina Bio)
10.12.1.1. Company Overview
10.12.2. Celltrion
10.12.2.1. Company Overview
10.12.3. Takara Bio
10.12.3.1. Company Overview

11.1. Chapter Overview
11.2. Bispecific Antibodies
11.2.1. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
11.2.2. Bispecific Antibodies: Pipeline Analysis
11.2.2.1. Analysis by Phase of Development
11.2.2.2. Analysis by Target Indication
11.2.3. Bispecific Antibody Therapeutics: Technology Platforms
11.2.4. Key Considerations for Manufacturing and Associated Challenges
11.2.5. Role of CMOs in Offering Services for Bispecific Antibodies
11.2.5.1. CMOs Offering Services for Bispecific Antibodies
11.3. Antibody Drug Conjugates (ADCs)
11.3.1. Components of ADCs
11.3.1.1. Antibody
11.3.1.2. Cytotoxin
11.3.1.3. Linker
11.3.2. Antibody Drug Conjugates (ADCs): Pipeline Analysis
11.3.2.1. Analysis by Status of Development
11.3.2.2. Analysis by Target Disease Indication
11.3.2.3. Most Active Players: Analysis by Number of Therapies
11.3.3. Antibody Drug Conjugate Developers
11.3.4. Manufacturing Process
11.4. Cell Therapies
11.4.1. Cell Therapies: Overall Market Landscape
11.4.2. Overview of Cell Therapy Manufacturing
11.4.2.1. Cell Therapy Manufacturing Models
11.4.2.1.1. Centralized Manufacturing
11.4.2.1.2. Decentralized Manufacturing
11.4.3. Key Challenges for Manufacturing Cell Therapies
11.4.4. Key Factors Impacting Cell Therapy Manufacturing
11.4.4.1. Characterization
11.4.4.2. Cost of Goods
11.4.4.3. Automation of Cell Therapy Manufacturing
11.4.5. Cell Therapies: Pipeline Analysis
11.4.5.1. Analysis by Type of Cell Manufactured
11.4.6. Stem Cell Therapies: Analysis by Phase of Development
11.4.7. T-Cell Therapies: Analysis by Phase of Development
11.4.8. Role of CMOs in Offering Services for Cell Therapies
11.4.8.1. CMOs Offering Services for Cell Therapies
11.5. Gene Therapies
11.5.1. Gene Therapies: Pipeline Analysis
11.5.1.1. Analysis by Stage of Development
11.5.1.2. Analysis by Phase of Development
11.5.1.3. Analysis by Type of Vector Used
11.5.1.3.1. Clinical Pipeline
11.5.1.3.2. Preclinical Pipeline
11.5.1.4. Analysis by Therapeutic Area
11.5.1.4.1. Clinical and Commercial Pipeline
11.5.1.4.2. Preclinical Pipeline
11.5.2. Role of CMOs in Offering Services for Gene Therapies
11.5.2.1. CMOs Offering Services for Gene Therapies
11.6. Viral Vectors
11.6.1. Viral Vectors: Pipeline Analysis
11.6.1.1. Analysis by Location of Viral Vectors Manufacturing Facilities
11.6.1.2. Analysis by Type of Viral Vector Manufactured
11.6.2. Role of CMOs in Offering Services for Viral Vectors
11.6.2.1. CMOs Offering Services for Viral Vectors
11.7. Plasmid DNA
11.7.1. Plasmid DNA: Pipeline Analysis
11.7.1.1. Analysis by Location of Manufacturing Facilities
11.7.2. Role of CMOs in Offering Services for Plasmid DNA
11.7.2.1. CMOs Offering Services for Plasmid DNA

12.1. Chapter Overview
12.2. Overview of Biosimilars
12.3. Development Stages of Biosimilars
12.4. Regulatory Requirements for Licensing of Biosimilars
12.5. Need for Outsourcing Manufacturing Operations
12.6. Impact of Biosimilars on the Global Contract Manufacturing Market
12.6.1. Biosimilars: Historical Trend of FDA Approvals
12.7. Biosimilars Contract Manufacturing Service Providers
12.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations

13.1. Chapter Overview
13.2. Small Molecule and Large Molecule Drugs / Therapies
13.2.1. Comparison of General Characteristics
13.2.2. Comparison of Key Specifications
13.2.3. Comparison of Manufacturing Process
13.2.4. Comparison of Key Manufacturing Challenges

14.1. Chapter Overview
14.2. In-House Manufacturing
14.2.1. Benefits Associated with In-House Manufacturing
14.2.2. Risks Associated with In-House Manufacturing
14.3. Outsourcing Trends in the Biopharmaceutical Industry
14.3.1. Types of Outsourcing Partners
14.4. Manufacturing Approaches Used for Approved Biologics, 2016-2022
14.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

15.1. Chapter Overview
15.2. Key Assumptions and Parameters
15.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
15.3.1. Scenario 1
15.3.2. Scenario 2
15.3.3. Scenario 3
15.3.4. Scenario 4
15.4. Conclusion

16.1. Chapter Overview
16.2. Biopharmaceutical Related Initiatives by Big Pharmaceutical Players
16.2.1. Analysis by Number of Initiatives
16.2.2. Analysis by Year of Initiative
16.2.3. Analysis by Purpose of Initiative
16.2.4. Analysis by Type of Initiative
16.2.4.1. Analysis by Type of Partnership
16.2.4.2. Analysis by Type of Expansion
16.2.5. Analysis by Scale of Operation
16.2.6. Analysis by Type of Biologic Manufactured
16.2.7. Analysis of Big Pharma Players by Year of Initiative
16.2.8. Analysis of Big Pharma Players by Purpose of Initiative
16.2.9. Analysis by Year and Type of Initiative
16.2.10. Analysis of Big Pharma Players by Region of Expansion
16.2.11. Analysis of Big Pharma Players by Type of Biologic Manufactured

17.1. Chapter Overview
17.2. Partnership Models
17.3. Biopharmaceutical Contract Manufacturing: Partnerships and Collaborations
17.3.1. Analysis by Year of Partnership
17.3.2. Analysis by Type of Partnership
17.3.3. Analysis by Year and Type of Partnership
17.3.4. Analysis by Type of Biologic Manufactured
17.3.5. Analysis by Year of Partnership and Type of Biologic Manufactured
17.3.6. Analysis by Type of Partnership and Type of Biologic Manufactured
17.3.7. Analysis by Scale of Operation
17.3.8. Analysis by Therapeutic Area
17.3.9. Most Active Players: Analysis by Number of Partnerships
17.3.10. Analysis by Geography
17.3.10.1. Local and International Agreements
17.3.10.2. Intracontinental and Intercontinental Agreements

18.1. Chapter Overview
18.2. Merger and Acquisition Models
18.3. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
18.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
18.3.2. Analysis by Type of Acquisition
18.3.3. Analysis by Geography
18.3.3.1. Local and International Mergers and Acquisitions
18.3.3.2. Intracontinental and Intercontinental Mergers and Acquisitions
18.3.3.3. Year-wise Trend in North America, Europe and Asia-Pacific
18.3.4. Most Active Acquirers: Analysis by Number of Acquisitions
18.3.5. Analysis by Key Value Drivers
18.3.6. Analysis by Year of Acquisition and Key Value Drivers
18.3.7. Analysis by Type of Biologic Manufactured
18.3.8. Analysis by Key Value Drivers and Type of Biologic Manufactured
18.4. Key Acquisitions: Deal Multiples
18.4.1. Year-wise Trend of Deal Multiple Amount

19.1. Chapter Overview
19.2. Biopharmaceutical Contract Manufacturing: Recent Expansions
19.2.1. Analysis by Year of Expansion
19.2.2. Analysis by Purpose of Expansion
19.2.3. Analysis by Year and Purpose of Expansion
19.2.4. Analysis by Type of Biologic Manufactured
19.2.5. Analysis by Purpose of Expansion and Type of Biologic Manufactured
19.2.6. Analysis by Location of Expanded Facility
19.2.7. Most Active Players: Analysis by Number of Recent Expansions
19.2.8. Analysis by Purpose of Expansion and Location of Expanded Facility
19.2.9. Analysis by Amount Invested
19.2.10. Recent Expansions: 2016-2020 and 2021-2023 Scenario

20.1. Chapter Overview
20.2. Types of Funding
20.3. Biopharmaceutical Contract Manufacturing: Funding and Investment Analysis
20.3.1. Analysis by Year of Funding
20.3.2. Analysis by Amount Invested
20.3.3. Analysis by Type of Funding
20.3.4. Analysis by Year and Type of Funding
20.3.5. Analysis of Funding Instances and Amount Invested by Geography (Continent)
20.3.6. Analysis of Funding Instances and Amount Invested by Geography (Country)
20.3.7. Most Active Players: Analysis by Number of Funding Instances
20.3.8. Most Active Players: Analysis by Total Amount Raised
20.3.9. Leading Investors: Analysis by Number of Funding Instances
20.3.10. Leading Investors: Analysis by Total Amount Raised
20.4. Technological Advancements
20.4.1. Single-Use Technology
20.4.2. Process Analytical Technology (PAT)
20.4.3. Continuous Processing
20.4.4. Quality by Design (QbD) in Bio-processing
20.4.5. Modular / Podular Biopharma Facilities

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Biopharmaceutical Contract Manufacturing: Global Installed Capacity
21.3.1. Analysis by Company Size
21.3.2. Analysis by Type of Expression System Used
21.3.3. Analysis by Geography
21.3.3.1. Analysis of Biopharmaceutical Contract Manufacturing Capacity in North America
21.3.3.2. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Europe
21.3.3.3. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
21.3.3.4. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
21.4. Concluding Remarks

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Global Demand for Biopharmaceuticals
22.4. Global Demand for Emerging Novel Biologics
22.4.1. Global Demand for ADC Therapeutics
22.4.2. Global Demand for Cell Therapy Manufacturing

23.1. Chapter Overview
23.2. Key Parameters
23.3. Assumptions and Methodology
23.4. Total Cost of Ownership (Sample Dataset)
23.5. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
23.5.1. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0
23.5.2. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20
23.6. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
23.6.1. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0
23.6.2. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20

24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
24.3.1. Scenario Analysis
24.3.1.1. Conservative Scenario
24.3.1.2. Optimistic Scenario
24.4. Key Market Segmentations

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, Current Year and 2035
25.3.1. API Manufacturing: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
25.3.2. FDF Manufacturing: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, Current Year and 2035
26.3.1. Antibodies: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
26.3.2. Cell Therapies: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
26.3.3. Vaccines: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
26.3.4. Other Biologics: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
26.4. Data Triangulation and Validation

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, Current Year and 2035
27.3.1. Mammalian Expression Systems: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
27.3.2. Microbial Expression Systems: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
27.3.3. Other Expression Systems: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
27.4. Data Triangulation and Validation

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, Current Year and 2035
28.3.1. Preclinical / Clinical Operations: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
28.3.2. Commercial Operations: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, Current Year and 2035
29.3.1. Small Companies: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
29.3.2. Mid-sized Companies: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
29.3.3. Large and Very Large Companies: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
29.4. Data Triangulation and Validation

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035
30.3.1. North America: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.1.1. US: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.1.2. Canada: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.2. Europe: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.2.1. Italy: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.2.2. Germany: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.2.3. France: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.2.4. Spain: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.2.5. UK: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.2.6. Rest of Europe: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.3. Asia-Pacific: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.3.1. China: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.3.2. India: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.3.3. South Korea: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.3.4. Japan: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.3.5. Rest of Asia-Pacific: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.4. Latin America: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.3.5. Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.4. Data Triangulation and Validation

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players
31.4. Data Triangulation and Validation

32.1. Chapter Overview
32.2. Historical Evolution of the Virtual Business Model
32.3. Virtual Pharmaceutical Companies as a Subset of the Overall Biopharmaceutical Industry
32.4. Advantages Associated with Outsourcing Operations to Virtual Service Providers
32.5. Key Challenges Associated with Outsourcing Operations to Virtual Service Providers

33.1. Chapter Overview
33.2. Strengths
33.3. Weaknesses
33.4. Opportunities
33.5. Threats
33.6. Comparison of SWOT Factors
33.7. Conclusion

34.1. Chapter Overview
34.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
34.3. Shift from One-time Contracts to Strategic Partnerships
34.4. Integration / Adoption of New and Innovative Technologies
34.4.1. Single-use Bioreactors
34.4.2. Novel Bioprocess Techniques
34.4.3. Bioprocess Automation
34.5. Focus on Niche Therapeutic Areas
34.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
34.7. Capability Expansion by CMOs to become One-Stop-Shops
34.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
34.9. Increase in Financial Inflow and Outsourcing Budgets
34.10. Challenges Faced by Sponsors and Service Providers
34.10.1. Concerns Related to Single-use Systems
34.10.2. Issues Related to Capacity Fluctuations
34.11. Concluding Remarks

36.1. Chapter Overview
36.2. RoslinCT
36.2.1. Company Snapshot
36.2.2. Interview Transcript: Peter Coleman, Chief Executive Officer
36.3. JAFRAL Biosolutions
36.3.1. Company Snapshot
36.3.2. Interview Transcript: Frenk Smrekar, Chief Executive Officer And Co-Founder
36.4. Discovery Life Sciences
36.4.1. Company Snapshot
36.4.2. Interview Transcript: Dominic Clarke, Chief Technical Officer, Cell And Gene Therapy
36.5. Bioworkshops
36.5.1. Company Snapshot
36.5.2. Interview Transcript: Nick Kotlarski, President and Chief Operating Officer
36.6. Aldevron
36.6.1. Company Snapshot
36.6.2. Interview Transcript: Jeff Briganti, Senior Director Of Global Strategic Marketing
36.7. Resilience
36.7.1. Company Snapshot
36.7.2. Interview Transcript: Tarek Abdel-Gawad, Senior Director of Commercial Strategy and Market Insights
36.8. Minaris Regenerative Medicine
36.8.1. Company Snapshot
36.8.2. Interview Transcript: Luc St-Onge, Global Head of Sales and Marketing and Head of Business Development (Germany)
36.9. 53Biologics
36.9.1. Company Snapshot
36.9.2. Interview Transcript: Francisco Manuel Reyes Sosa, Business Development Manager
36.10. Richter-Helm BioLogics
36.10.1. Company Snapshot
36.10.2. Interview Transcript Antje Weingarth, Manager Marketing and Sales

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Overall Market Landscape
Figure 4.2 Executive Summary: Regional Capability Analysis
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Mergers and Acquisitions
Figure 4.5 Executive Summary: Recent Expansions
Figure 4.6 Executive Summary: Funding and Investment Analysis
Figure 4.7 Executive Summary: Demand Analysis
Figure 4.8 Executive Summary: Total Cost of Ownership
Figure 4.9 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Types of Biopharmaceuticals
Figure 5.2 Types of Expression Systems Used for the Production of Biopharmaceuticals
Figure 5.3 Stages of the Biomanufacturing Process
Figure 5.4 Types of Third-Party Service Providers
Figure 5.5 Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations
Figure 6.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Figure 6.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Figure 6.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)
Figure 6.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Figure 6.5 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region)
Figure 6.6 Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Figure 6.7 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Figure 6.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters (Region)
Figure 6.9 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Company Size
Figure 6.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Figure 6.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Figure 6.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Figure 6.13 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used and Location of Headquarters (Region)
Figure 6.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Figure 6.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Figure 7.1 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Figure 7.2 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered
Figure 7.3 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Figure 7.4 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
Figure 7.5 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
Figure 7.6 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Figure 7.7 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Figure 8.1 Biopharmaceutical Contract Manufacturing Industry: The US Market Scenario
Figure 8.2 Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
Figure 8.3 US FDA Guidelines: Elements of a Quality Agreement
Figure 8.4 US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations
Figure 8.5 AGC Biologics: Annual Revenues, Since FY 2018 (JPY Billion)
Figure 8.6 Catalent: Service Portfolio
Figure 8.7 Catalent: Biosimilars Service Portfolio
Figure 8.8 Catalent: Annual Revenues, Since FY-2018 (USD Billion)
Figure 8.9 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 8.10 FUJIFILM Diosynth Biotechnologies: Annual Revenues, Since FY 2018 (JPY Billion)
Figure 8.11 FUJIFILM Holdings: Annual Revenues by Business Divisions, Current Year (JPY Billion)
Figure 8.12 KBI Biopharma: Service Portfolio
Figure 8.13 Charles River Laboratories: Service Portfolio
Figure 8.14 Charles River Laboratories: Annual Revenues, Since FY 2018 (USD Billion)
Figure 9.1 Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 9.2 EMA GMP Guidelines: Key Considerations for the Contract Giver, Contract Acceptor and the Contract
Figure 9.3 Boehringer Ingelheim (BioXcellenece): Service Portfolio
Figure 9.4 Boehringer Ingelheim: Annual Revenues, Since FY 2018 (EUR Billion)
Figure 9.5 Lonza: Service Portfolio
Figure 9.6 Lonza: Annual Revenues, Since FY 2018 (CHF Billion)
Figure 9.7 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Figure 9.8 Sandoz: Annual Revenues, Since FY 2018 (USD Billion)
Figure 9.9 Vetter Pharma: Service Portfolio
Figure 10.1 Chinese Regulatory Guidelines: Key Considerations for the Contract Giver
Figure 10.2 Chinese Regulatory Guidelines: Key Considerations for the Contract Acceptor
Figure 10.3 Chinese Regulatory Guidelines: Key Aspects of the Contract
Figure 10.4 WuXi Biologics: Service Portfolio
Figure 10.5 Wuxi Biologics: Annual Revenues, Since FY 2018 (RMB Billion)
Figure 10.6 Biopharmaceutical Contract Manufacturing in India: Growth Drivers
Figure 10.7 Kemwell Biopharma: Service Portfolio
Figure 10.8 Minaris Regenerative Medicine: Service Portfolio
Figure 10.9 Samsung Biologics: Service Portfolio
Figure 10.10 Samsung Biologics: Annual Revenues, Since FY 2018 (KRW Billion)
Figure 10.11 Cell Therapies: Service Portfolio
Figure 11.1 Basic Structure of an Antibody
Figure 11.2 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Figure 11.3 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Figure 11.4 Structure of an Antibody Drug Conjugate (ADC)
Figure 11.5 Antibody Drug Conjugates: Distribution by Status of Development
Figure 11.6 Antibody Drug Conjugates: Distribution by Target Disease Indication
Figure 11.7 Most Active Players: Distribution by Number of Therapies
Figure 11.8 Decentralized Manufacturing: Process Model
Figure 11.9 Cell Therapies: Challenges and Drivers
Figure 11.10 Cell Therapies: Potency as Critical Quality Attribute
Figure 11.11 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Figure 11.12 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Figure 11.13 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Figure 11.14 Stem Cell Therapies: Distribution by Phase of Development
Figure 11.15 T-Cell Therapies: Distribution by Phase of Development
Figure 11.16 Gene Therapies: Distribution by Stage of Development
Figure 11.17 Gene Therapies: Distribution by Phase of Development
Figure 11.18 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Figure 11.19 Early-stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Figure 11.20 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 11.21 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 11.22 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise)
Figure 11.23 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 11.24 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Figure 12.1 Manufacturing Stages of a Biosimilar Product
Figure 12.2 Analytical and Functional Characterization Methods for Key Biosimilar Product
Figure 12.3 Regulatory Process Adopted for Licensing of a Biosimilar Product
Figure 12.4 Need for Outsourcing Biosimilar Manufacturing Operations
Figure 12.5 Biosimilars: Historical Trend of FDA Approvals, Since 2015
Figure 12.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations
Figure 13.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022
Figure 13.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 14.1 Benefits Associated with In-House Manufacturing
Figure 14.2 Risks Associated with In-House Manufacturing
Figure 14.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships
Figure 15.1 Make versus Buy Decision Making Framework
Figure 15.2 Make versus Buy Decision Making Framework: Possible Scenarios
Figure 16.1 Big Pharma Initiatives: Distribution of Players by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives
Figure 16.2 Big Pharma Initiatives: Cumulative Year-wise Trend, Since 2005
Figure 16.3 Big Pharma Initiatives: Distribution by Purpose of Initiative
Figure 16.4 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 16.5 Big Pharma Initiatives: Distribution by Type of Partnership
Figure 16.6 Big Pharma Initiatives: Distribution by Type of Expansion
Figure 16.7 Big Pharma Initiatives: Distribution by Scale of Operation
Figure 16.8 Big Pharma Initiatives: Distribution by Type of Biologic Manufactured
Figure 16.9 Big Pharma Initiatives: Distribution of Players by Year and Number of Initiatives
Figure 16.10 Big Pharma Initiatives: Distribution of Players by Purpose of Initiative
Figure 16.11 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Figure 16.12 Big Pharma Initiatives: Distribution of Players by Region of Expansion
Figure 16.13 Big Pharma Initiatives: Distribution of Players by Type of Biologic Manufactured
Figure 17.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
Figure 17.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 17.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 17.4 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Figure 17.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Figure 17.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured
Figure 17.7 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 17.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 17.9 Most Active Players: Distribution by Number of Partnerships
Figure 17.10 Partnerships and Collaborations: Local and International Agreements
Figure 17.11 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 18.1 Mergers and Acquisitions: Year-Wise Cumulative Trend, Since 2015
Figure 18.2 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 18.3 Local and International Mergers and Acquisitions
Figure 18.4 Intracontinental and Intercontinental Mergers and Acquisitions
Figure 18.5 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific, Since 2015
Figure 18.6 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 18.7 Catalent Biologics: Information on Key Acquisitions
Figure 18.8 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 18.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 18.10 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Figure 18.11 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Figure 18.12 Mergers and Acquisitions: Year-Wise Trend of Deal Multiple Amount (USD Million)
Figure 19.1 Recent Expansions: Cumulative Year-wise Trend, Since 2016
Figure 19.2 Recent Expansions: Distribution by Purpose of Expansion
Figure 19.3 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 19.4 Recent Expansions: Distribution by Type of Biologic Manufactured
Figure 19.5 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Figure 19.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 19.7 Most Active Players: Distribution by Number of Recent Expansions
Figure 19.8 Recent Expansions: Distribution by Purpose of
Figure 19.9 Recent Expansions: Distribution by Amount Invested (USD Million)Figure 19.10 Recent Expansions: Comparison 2016-2020 and 2021-2023 Scenario
Figure 19.10 Recent Expansions: Regional Comparison 2016-2020 and 2021-2023 Scenario
Figure 20.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2016
Figure 20.2 Funding and Investment Analysis: Cumulative Year-wise Trend by Amount Invested, Since 2016 (USD Million)
Figure 20.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Figure 20.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 20.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 20.6 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Continent) (USD Million)
Figure 20.7 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Country) (USD Million)
Figure 20.8 Most Active Players: Distribution by Number of Funding Instances
Figure 20.9 Most Active Players: Distribution by Total Amount Raised (USD Million)
Figure 20.10 Leading Investors: Distribution by Number of Funding Instances
Figure 20.11 Leading Investors: Distribution by Amount Invested (USD Million)
Figure 21.1 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Company Size
Figure 21.2 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Type of Expression System Used
Figure 21.3 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Location of Manufacturing Facilities
Figure 21.4 Biopharmaceutical Contract Manufacturing Capacity in North America
Figure 21.5 Biopharmaceutical Contract Manufacturing Capacity in Europe
Figure 21.6 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Figure 21.7 Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Figure 22.1 Global Demand for Biopharmaceuticals, till 2035 (in kilograms)
Figure 22.2 Global Demand for ADC Therapeutics, till 2035 (in kilograms)
Figure 22.3 Global Demand for Cell Therapies, till 2035 (in terms of Number of Patients)
Figure 22.4 Global Demand for Cell Therapies, till 2035 (Billion Cells)
Figure 23.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 23.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 23.3 Total Cost of Ownership for Mid-sized Biopharmaceutical
Figure 23.4 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 23.5 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 23.6 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 23.7 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 23.8 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 24.1 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (Since 2018)
Figure 24.2 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Base Scenario (USD Billion)
Figure 24.3 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Billion)
Figure 24.4 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
Figure 25.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, Current Year and 2035
Figure 25.2 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 25.3 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, Current Year and 2035
Figure 26.2 Biopharmaceutical Contract Manufacturing Market for Antibodies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.3 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.4 Biopharmaceutical Contract Manufacturing Market for Vaccines, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, Current Year and 2035
Figure 27.2 Biopharmaceutical Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.3 Biopharmaceutical Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.4 Biopharmaceutical Contract Manufacturing Market for Other Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 28.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, Current Year and 2035
Figure 28.2 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, Historical Trends (Since 2018) and Forecasted Estimates (till2035) (USD Billion)
Figure 28.3 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, Historical Trends (Since 2018 and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, Current Year and 2035
Figure 29.2 Biopharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.3 Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.4 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography, 2018, Current Year and 2035
Figure 30.2 Biopharmaceutical Contract Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.3 Biopharmaceutical Contract Manufacturing Market in the US, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.4 Biopharmaceutical Contract Manufacturing Market in Canada, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.5 Biopharmaceutical Contract Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.6 Biopharmaceutical Contract Manufacturing Market in Italy, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.7 Biopharmaceutical Contract Manufacturing Market in Germany, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.8 Biopharmaceutical Contract Manufacturing Market in France, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD
Figure 30.9 Biopharmaceutical Contract Manufacturing Market in Spain, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.10 Biopharmaceutical Contract Manufacturing Market in the UK, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.11 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.12 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.13 Biopharmaceutical Contract Manufacturing Market in China, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.14 Biopharmaceutical Contract Manufacturing Market in India, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.15 Biopharmaceutical Contract Manufacturing Market in South Korea, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.16 Biopharmaceutical Contract Manufacturing Market in Japan, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.17 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.18 Biopharmaceutical Contract Manufacturing Market in Latin America, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.19 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.20 Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players (USD Billion)
Figure 31.1 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market (USD Billion)
Figure 31.2 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market in 2023 (USD Billion)
Figure 32.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
Figure 32.2 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2022
Figure 32.3 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 35.1 Concluding Remarks: Overall Market Landscape
Figure 35.2 Concluding Remarks: Partnerships and Collaborations
Figure 35.3 Concluding Remarks: Mergers and Acquisitions
Figure 35.4 Concluding Remarks: Funding and Investments
Figure 35.5 Concluding Remarks: Recent Expansions
Figure 35.6 Concluding Remarks: Capacity Analysis
Figure 35.7 Concluding Remarks: Demand Analysis
Figure 35.8 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 35.9 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)

Table 5.1 Mammalian versus Microbial Expression Systems
Table 6.1 List of Biopharmaceutical Contract Manufacturers
Table 6.2 Biopharmaceutical Contract Manufacturers: Information on Type of Service Offered
Table 6.3 Biopharmaceutical Contract Manufacturers: Information on Type of Biologic Manufactured
Table 6.4 Biopharmaceutical Contract Manufacturers: Information on Scale of Operation
Table 6.5 Biopharmaceutical Contract Manufacturers: Information on Type of Expression System Used
Table 6.6 Biopharmaceutical Contract Manufacturers: Information on Type of Bioreactor Used
Table 6.7 Biopharmaceutical Contract Manufacturers: Information on Mode of Operation of Bioreactor
Table 7.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 7.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 7.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Table 7.4 List of Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Table 8.1 AGC Biologics: Company Overview
Table 8.2 AGC Biologics: Biologics Manufacturing Facilities
Table 8.3 AGC Biologics: Recent Developments and Future Outlook
Table 8.4 Catalent: Company Overview
Table 8.5 Catalent: Biologics Manufacturing Facilities
Table 8.6 Catalent: Recent Developments and Future Outlook
Table 8.7 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 8.8 FUJIFILM Diosynth Biotechnologies: Biologics Manufacturing Facilities
Table 8.9 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 8.10 KBI Biopharma: Company Overview
Table 8.11 KBI Biopharma: Biologics Manufacturing Facilities
Table 8.12 KBI Biopharma: Recent Developments and Future Outlook
Table 8.13 Charles River Laboratories: Company Overview
Table 8.14 Charles River Laboratories: Biologics Manufacturing Facilities
Table 8.15 Charles River Laboratories: Recent Developments and Future Outlook
Table 8.16 Cytiva: Company Overview
Table 8.17 Patheon: Company Overview
Table 8.18 Piramal Pharma Solutions: Company Overview
Table 9.1 FDA Quality Agreements and EMA cGMP Regulations: A
Table 9.2 Boehringer Ingelheim:
Table 9.3 Boehringer Ingelheim:
Table 9.4 Boehringer Ingelheim: Recent Developments and Future Outlook
Table 9.5 Lonza: Company Overview
Table 9.6 Lonza: Biologics Manufacturing Facilities
Table 9.7 Lonza: Recent Developments and Future Outlook
Table 9.8 Sandoz: Company Overview
Table 9.9 Sandoz: Biologics Manufacturing Facilities
Table 9.10 Sandoz: Recent Developments and Future Outlook
Table 9.11 Vetter Pharma: Company Overview
Table 9.12 Vetter Pharma: Biologics Manufacturing Facilities
Table 9.13 Vetter Pharma: Recent
Table 9.14 Miltenyi Biotec: Company Overview
Table 9.15 Miltenyi Biotec: Biologics Manufacturing Facilities
Table 9.16 Miltenyi Biotec: Recent Developments and Future Outlook
Table 9.17 Novasep: Company Overview
Table 9.18 Olon: Company Overview
Table 9.19 Rentschler Biopharma: Company Overview
Table 10.1 WuXi Biologics: Company Overview
Table 10.2 Wuxi Biologics: Biologics Manufacturing Facilities
Table 10.3 WuXi Biologics: Recent Developments and Future Outlook
Table 10.4 Kemwell Biopharma: Company Overview
Table 10.5 Kemwell Biopharma: Recent Developments and Future Outlook
Table 10.6 Minaris Regenerative Medicine: Company Overview
Table 10.7 Minaris Regenerative Medicine: Biologics Manufacturing Facilities
Table 10.8 Minaris Regenerative Medicine: Recent Developments and Future Outlook
Table 10.9 Samsung BioLogics: Company Overview
Table 10.10 Samsung BioLogics: Biologics Manufacturing Facilities
Table 10.11 Samsung BioLogics: Recent Developments and Future Outlook
Table 10.12 Cell Therapies: Company Overview
Table 10.13 Cell Therapies: Recent Developments and Future Outlook
Table 10.14 AcuraBio: Company Overview
Table 10.15 Celltrion: Company Overview
Table 10.16 Takara Bio: Company Overview
Table 11.1 Bispecific Antibody Therapeutics: Information on Drug Candidate, Developer, Phase of Development and Target Antigen
Table 11.2 Bispecific Antibody Therapeutics: Information on Clinical Drug Candidates, Target Indications, Therapeutic Areas and Disease Segment
Table 11.3 Bispecific Antibody Therapeutics: List of Technology Platforms
Table 11.4 Bispecific Antibody Contract Manufacturers: List of Companies
Table 11.5 Commonly Used Cytotoxins for ADC Therapeutics
Table 11.6 Occupational Exposure Limit Bands, Safebridge Consultants
Table 11.7 Antibody Drug Conjugates: Information on Drug Candidates, Developers, Status of Development, Target Disease Indications and
Table 11.8 Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 11.9 ADC Contract Manufacturers: List of Companies
Table 11.10 Cell-based Therapies: Applications
Table 11.11 Cell-based Therapies: Commercialized Products,
Table 11.12 Key Cell Therapy Manufacturing Steps
Table 11.13 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 11.14 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
Table 11.15 Cell Therapy Contract Manufacturers: List of Companies
Table 11.16 Gene Therapy Contract Manufacturers: List of Companies
Table 11.17 Vector and Gene Therapy Manufacturers (Non-Industry players): Information on Type of Vector Manufactured
Table 11.18 Viral Vectors Contract Manufacturers: List of Companies
Table 11.19 Plasmid DNA Manufacturing Service Providers: Information on Location of Manufacturing Facility
Table 11.20 Plasmid DNA Contract Manufacturers: List of Companies
Table 12.1 List of Biosimilars Contract Manufacturing Service Providers
Table 13.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 13.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 13.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 14.1 List of FDA Approved
Table 16.1 Big Pharma Initiatives: List of Biopharmaceutical Manufacturing Initiatives
Table 17.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, Since 2019
Table 17.2 Partnerships and Collaborations: Information on Type of Biologic Manufactured
Table 18.1 Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, Since 2015
Table 18.2 Mergers and Acquisitions: Information on Key Value Drivers and Type of Biologic Manufactured
Table 18.3 Mergers and Acquisitions: Information on Deal Multiples, Since 2015
Table 19.1 Biopharmaceutical Contract Manufacturing: List of Recent Expansions, Since 2016
Table 20.1 Biopharmaceutical Contract Manufacturing: List of Funding and Investments, Since 2016
Table 20.2 Funding and Investment Analysis: Summary of Investments
Table 20.3 Funding and Investment Analysis: Summary of Venture Capital Funding
Table 21.1 Biopharmaceutical Contract Manufacturers: Information on Capacity (Sample Data Set)
Table 21.2 Capacity Analysis: Average Capacity per Category (Sample Data Set)
Table 21.3 Capacity Analysis: Average Capacity for Mammalian Expression Systems (Sample Data Set)
Table 21.4 Capacity Analysis: Average Capacity for Microbial Expression Systems (Sample Data Set)
Table 21.5 Capacity Analysis: Average Capacity for Other Expression Systems (Sample Data Set)
Table 21.6 Capacity Analysis: Global Production Capacity
Table 22.1 Annual Biomanufacturing Capacity, till 2035 (Million Liters)
Table 23.1 Total Cost of Ownership: Sample Dataset for Mid-sized Companies
Table 23.2 Total Cost of Ownership: Sample Dataset for Large / Very Large Companies
Table 31.1 List of Leading Biopharmaceutical Contract Manufacturing Companies
Table 32.1 List of Virtual Biopharmaceutical Companies
Table 36.1 RoslinCT: Key Highlights
Table 36.2 Jafral Biosolutions: Key Highlights
Table 36.3 Discovery Life Sciences: Key Highlights
Table 36.4 Bioworkshops: Key Highlights
Table 36.5 Aldevron: Key Highlights
Table 36.6 Resilience: Key Highlights
Table 36.7 Minaris Regenerative Medicine: Key Highlights
Table 36.8 53Biologics: Key Highlights
Table 36.9 Richter-Helm BioLogics: Key Highlights
Table 37.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Table 37.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Table 37.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)
Table 37.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 37.5 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region)
Table 37.6 Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Table 37.7 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Table 37.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters (Region)
Table 37.9 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Company Size
Table 37.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Table 37.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Table 37.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Table 37.13 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used and Location of Headquarters (Region)
Table 37.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Table 37.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Table 37.16 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Table 37.17 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered
Table 37.18 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 37.19 AGC Biologics: Annual Revenues, Since FY 2018 (JPY Billion)
Table 37.20 Catalent: Annual Revenues, Since FY-2018 (USD Billion)
Table 37.21 FUJIFILM Diosynth Biotechnologies: Annual Revenues, Since FY 2018 (JPY Billion)
Table 37.22 FUJIFILM Holdings: Annual Revenues by Business Divisions, Current Year (JPY Billion)
Table 37.23 Charles River Laboratories: Annual Revenues, Since FY 2018 (USD Billion)
Table 37.24 Boehringer Ingelheim: Annual Revenues, Since FY 2018 (EUR Billion)
Table 37.25 Lonza: Annual Revenues, Since FY 2018 (CHF Billion)
Table 37.26 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Table 37.27 Sandoz: Annual Revenues, Since FY 2018 (USD Billion)
Table 37.28 Wuxi Biologics: Annual Revenues, Since FY 2018 (RMB Billion)
Table 37.29 Samsung Biologics: Annual Revenues, Since FY 2018 (KRW Billion)
Table 37.30 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 37.31 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Table 37.32 Antibody Drug Conjugates: Distribution by Status of Development
Table 37.33 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 37.34 Most Active Players: Distribution by Number of Therapies
Table 37.35 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Table 37.36 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Table 37.37 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Table 37.38 Stem Cell Therapies: Distribution by Phase of Development
Table 37.39 T-Cell Therapies: Distribution by Phase of Development
Table 37.40 Gene Therapies: Distribution by Stage of Development
Table 37.41 Gene Therapies: Distribution by Phase of Development
Table 37.42 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 37.43 Early-stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 37.44 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 37.45 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 37.46 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise)
Table 37.47 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 37.48 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 37.49 Biosimilars: Historical Trend of FDA Approvals, Since 2015
Table 37.50 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022
Table 37.51 Big Pharma Initiatives: Distribution of Players by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives
Table 37.52 Big Pharma Initiatives: Cumulative Year-wise Trend, Since 2005
Table 37.53 Big Pharma Initiatives: Distribution by Purpose of Initiative
Table 37.54 Big Pharma Initiatives: Distribution by Type of Initiative
Table 37.55 Big Pharma Initiatives: Distribution by Type of Partnership
Table 37.56 Big Pharma Initiatives: Distribution by Type of Expansion
Table 37.57 Big Pharma Initiatives: Distribution by Scale of Operation
Table 37.58 Big Pharma Initiatives: Distribution by Type of Biologic Manufactured
Table 37.59 Big Pharma Initiatives: Distribution of Players by Purpose of Initiative
Table 37.60 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Table 37.61 Big Pharma Initiatives: Distribution of Players by Region of Expansion
Table 37.62 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
Table 37.63 Partnerships and Collaborations: Distribution by Type of Partnership
Table 37.64 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 37.65 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Table 37.66 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Table 37.67 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured and Geography
Table 37.68 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured
Table 37.69 Partnerships and Collaborations: Distribution by Scale of Operation
Table 37.70 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 37.71 Most Active Players: Distribution by Number of Partnerships
Table 37.72 Partnerships and Collaborations: Local and International Agreements
Table 37.73 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 37.74 Mergers and Acquisitions: Year-Wise Cumulative Trend, Since 2015
Table 37.75 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 37.76 Local and International Mergers and Acquisitions
Table 37.77 Intracontinental and Intercontinental Mergers and Acquisitions
Table 37.78 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific, Since 2015
Table 37.79 Most Active Acquirers: Distribution by Number of Acquisitions
Table 37.80 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 37.81 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 37.82 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Table 37.83 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Table 37.84 Mergers and Acquisitions: Year-Wise Trend of Deal Multiple Amount (USD Million)
Table 37.85 Recent Expansions: Cumulative Year-wise Trend, Since 2016
Table 37.86 Recent Expansions: Distribution by Purpose of Expansion
Table 37.87 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 37.88 Recent Expansions: Distribution by Type of Biologic Manufactured
Table 37.89 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Table 37.90 Recent Expansions: Distribution by Location of Expanded Facility
Table 37.91 Most Active Players: Distribution by Number of Recent Expansions
Table 37.92 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
Table 37.93 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 37.94 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2016
Table 37.95 Funding and Investment Analysis: Cumulative Year-wise Trend by Amount Invested, Since 2016 (USD Million)
Table 37.96 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Table 37.97 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 37.98 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 37.99 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Continent) (USD Million)
Table 37.100 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Country) (USD Million)
Table 37.101 Most Active Players: Distribution by Number of Funding Instances
Table 37.102 Most Active Players: Distribution by Total Amount Raised (USD Million)
Table 37.103 Leading Investors: Distribution by Number of Funding Instances
Table 37.104 Leading Investors: Distribution by Amount Invested (USD Million)
Table 37.105 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Company Size
Table 37.106 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Type of Expression System Used
Table 37.107 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Location of Manufacturing Facilities
Table 37.108 Biopharmaceutical Contract Manufacturing Capacity in North America
Table 37.109 Biopharmaceutical Contract Manufacturing Capacity in Europe
Table 37.110 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Table 37.111 Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Table 37.112 Global Demand for Biopharmaceuticals, till 2035 (in kilograms)
Table 37.113 Global Demand for ADC Therapeutics, till 2035 (in kilograms)
Table 37.114 Global Demand for Cell Therapies, till 2035 (in terms of Number of Patients)
Table 37.115 Global Demand for Cell Therapies, till 2035 (Billion Cells)
Table 37.116 Total Cost of Ownership: Capital Expenditures (CAPEX)
Table 37.117 Total Cost of Ownership: Operational Expenditures (OPEX)
Table 37.118 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 37.119 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 37.120 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 37.121 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 37.122 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 37.123 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 37.124 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (Since 2018)
Table 37.125 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Base Scenario (USD Billion)
Table 37.126 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Billion)
Table 37.127 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
Table 37.128 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, Current Year and 2035 (USD Billion)
Table 37.129 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.130 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.131 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, Current Year and 2035 (USD Billion)
Table 37.132 Biopharmaceutical Contract Manufacturing Market for Antibodies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.133 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.134 Biopharmaceutical Contract Manufacturing Market for Vaccines, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.135 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, Current Year and 2035 (USD Billion)
Table 37.136 Biopharmaceutical Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.137 Biopharmaceutical Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.138 Biopharmaceutical Contract Manufacturing Market for Other Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.139 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, Current Year and 2035 (USD Billion)
Table 37.140 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.141 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, Historical Trends (Since 2018 and Forecasted Estimates (till 2035) (USD Billion)
Table 37.142 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, Current Year and 2035 (USD Billion)
Table 37.143 Biopharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.144 Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.145 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.146 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography, 2018, Current Year and 2035 (USD Billion)
Table 37.147 Biopharmaceutical Contract Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.148 Biopharmaceutical Contract Manufacturing Market in the US, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.149 Biopharmaceutical Contract Manufacturing Market in Canada, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.150 Biopharmaceutical Contract Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.151 Biopharmaceutical Contract Manufacturing Market in Italy, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.152 Biopharmaceutical Contract Manufacturing Market in Germany, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.153 Biopharmaceutical Contract Manufacturing Market in France, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD
Table 37.154 Biopharmaceutical Contract Manufacturing Market in Spain, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.155 Biopharmaceutical Contract Manufacturing Market in the UK, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.156 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.157 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.158 Biopharmaceutical Contract Manufacturing Market in China, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.159 Biopharmaceutical Contract Manufacturing Market in India, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.160 Biopharmaceutical Contract Manufacturing Market in South Korea, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.161 Biopharmaceutical Contract Manufacturing Market in Japan, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.162 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.163 Biopharmaceutical Contract Manufacturing Market in Latin America, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.164 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.165 Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players (USD Billion)
Table 37.166 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market (USD Billion)
Table 37.167 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market in 2023 (USD Billion)
Table 37.168 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2023
Table 39.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, 2015 - 2018